{"contentid": 488507, "importid": NaN, "name": "Create an agile regulatory framework and maintain a strong incentives\u00e2\u0080\u0099 system, says EFPIA in EU roadmap comments", "introduction": "The European Federation of Pharmaceutical Industries and Associations (EFPIA) has filed its response to the European Union (EU) roadmap/IIA on the Evaluation and revision of the general pharmaceutical legislation.", "content": "<p>The European Federation of Pharmaceutical Industries and Associations (EFPIA) has <a href=\"https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12963-Evaluation-and-revision-of-the-general-pharmaceutical-legislation/F2242371\" target=\"_blank\" rel=\"follow noopener\">filed its response</a> to the European Union (EU) roadmap/IIA on the Evaluation and revision of the general pharmaceutical legislation.</p>\n<p>This roadmap contains proposed priorities for legislative change to equip the regulatory framework to respond quickly to the needs of patients across Europe.</p>\n<p><span class=\"pullQuote\">\"The evaluation of the general pharmaceutical legislation is a once-in-a-lifetime opportunity to make Europe a world leader in medical innovation\"</span>EFPIA director general Nathalie Moll said: &ldquo;The evaluation of the general pharmaceutical legislation is a once-in-a-lifetime opportunity to make Europe a world leader in medical innovation and build back better from the COVID-19 crisis. To achieve these goals, the focus must be on creating an agile regulatory framework and maintaining a strong incentives&rsquo; system that embrace and encourage advances in science, technology and medicines.&rdquo;</p>\n<p>The EFPIA has stressed that the goal of ensuring faster, more equitable access to medicines cannot be achieved through the revision of legislation and an incentives framework designed to inspire world-leading pharmaceutical innovation in Europe.</p>\n<p>The trade group argues that access issues are multifaceted and must be addressed by developing a shared understanding of the root causes of access barriers and delays, followed by working in partnership, through a high-level European forum on access to health innovation, to address these blockages and hold-ups wherever they occur.</p>\n<p>Ms Moll added: &ldquo;EFPIA and its member companies stand ready to work with the commission and all stakeholders to help develop a pharmaceutical legislation that can help Europe regain its place as a world leader in medical innovation, while at the same time working with the EU institutions, member states and healthcare partners to identify and address barriers and delays in access to medicines.&rdquo;&nbsp;</p>", "date": "2021-04-30 12:47:00", "meta_title": NaN, "meta_keywords": "pharmaceutical, EFPIA, legislation, European, general, evaluation, framework, Europe, innovation, regulatory, access, revision, roadmap, system, agile, goa", "meta_description": "The European Federation of Pharmaceutical Industries and Associations (EFPIA) has filed its response to the European Union (EU) roadmap/IIA on the Evaluation an", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 12:43:39", "updated": "2021-04-30 13:58:30", "access": NaN, "url": "https://www.thepharmaletter.com/article/create-an-agile-regulatory-framework-and-maintain-a-strong-incentives-system-says-efpia-in-eu-roadmap-comments", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "eu_europe_court_law_big.jpg", "image2id": "eu_europe_court_law_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": NaN, "topic_tag": "European Medicines Agency, Focus On, Government Affairs, Health Medical Pharma, Regulation", "geography_tag": "Europe", "company_tag": "EFPIA", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 12:47:00"}